Building on the success of the adoptive immunotherapy of cancer

以癌症过继免疫疗法的成功为基础

• 批准号: 9556354
• 负责人: Nicholas Restifo
• 金额: $ 217.58万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9556354
• 关键词: Adoptive Immunotherapy; Advanced Malignant Neoplasm; Animal Model; Antigen Targeting; Antigens; Biotechnology; CD8-Positive T-Lymphocytes; Characteristics; Clinical Trials; Collaborations; Goals; Human; Immune response; Immunotherapy; Interleukin 2 Receptor Gamma; Mediating; Memory; Metabolic; Molecular; Mutate; Patients; Process; Research Personnel; Scientist; Shapes; Signal Transduction; T-Cell Activation; T-Lymphocyte; Testing; Translating; base; cancer immunotherapy; cytokine; design; in vitro Assay; neoplastic cell; receptor; response; success; tumor

Adoptive immunotherapy for cancer: building on success. Substantial progress has been made in our understanding of the molecular and cellular bases of T cell mediated anti-tumor responses. T cells are potent effectors of the adaptive anti-tumor immune response. Some target antigens recognized by tumor-reactive CD8+ T cells are mutated antigens. The molecular signals that modulate T cell activation, function and memory are being elucidated. Both positive and negative signals from co-stimulatory molecules have been shown to shape the anti-tumor response. Cytokines, including those with receptors that contain the common cytokine-receptor gamma chain have been shown to alter the programming of effector CD8+ T cells. We are also characterizing the metabolic characteristics of T cells that are capable of destroying tumor. In addition, we have studied the mechanisms that tumor cells use to escape recognition by T cells.

癌症过继免疫疗法：以成功为基础。我们对 T 细胞介导的抗肿瘤反应的分子和细胞基础的理解取得了实质性进展。 T 细胞是适应性抗肿瘤免疫反应的有效效应器。肿瘤反应性 CD8+ T 细胞识别的一些靶抗原是突变抗原。调节 T 细胞激活、功能和记忆的分子信号正在被阐明。共刺激分子的正信号和负信号已被证明可以塑造抗肿瘤反应。细胞因子，包括那些含有共同细胞因子受体伽马链的受体，已被证明可以改变效应 CD8+ T 细胞的编程。我们还描述了能够破坏肿瘤的 T 细胞的代谢特征。此外，我们还研究了肿瘤细胞逃避 T 细胞识别的机制。